Elevance Health, Inc. (ELV)
(Delayed Data from NYSE)
$505.16 USD
-6.10 (-1.19%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $505.17 +0.01 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value F Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$505.16 USD
-6.10 (-1.19%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $505.17 +0.01 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value F Growth B Momentum C VGM
Zacks News
HCA Healthcare (HCA) Q2 Earnings Beat on Better Patient Volumes
by Zacks Equity Research
HCA Healthcare's (HCA) second-quarter results reflect improved revenues stemming from better same-facility emergency room visits. However, the results were partly offset by elevated salaries and benefits cost.
Elevance Health (ELV) Q2 Earnings Beat on Higher Premiums
by Zacks Equity Research
Elevance Health (ELV) hikes adjusted net income estimate for this year to more than $28.70 per share.
Anthem (ELV) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Anthem (ELV) delivered earnings and revenue surprises of 4.15% and 0.94%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Medpace (MEDP) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Medpace (MEDP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can Elevance Health (ELV) Beat Q2 Earnings on Membership Growth?
by Zacks Equity Research
Elevance Health's (ELV) second-quarter results are likely to reflect improved Commercial Business operations, driven by the robust growth in risk-based areas.
Anthem (ELV) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Anthem (ELV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
UnitedHealth (UNH) to Post Q2 Earnings: What to Expect?
by Zacks Equity Research
UnitedHealth Group's (UNH) second-quarter results are likely to reflect improving premiums, products and higher expenses.
Why You Should Hold Elevance Health (ELV) in Your Portfolio
by Zacks Equity Research
Elevance Health (ELV) continues witnessing a rise in the usage of its virtual care services, which is a vital driver.